MarketPeel
Insider Trading Intelligence
MH

Matthew C. Hill

PDSB
CHIEF FINANCIAL OFFICER · PDS BIOTECHNOLOGY CORP · CIK 0001278675
FILING MIX · LIFETIME100%/0%
BUYS
13
SELLS
0
TOTAL VALUE
$46.1K
COMPANIES
2
ACTIVE SINCE
Oct 2021
HOLDINGS NOW
293,266
AVG SELL PX
TRADE KIND
SHOWING 13 / 13
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
6 backtested trades · 8 horizons · 2 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Matthew C. Hill, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d6+50.00%+4.48%+0.41%+4.07%+0.04%
14d6+50.00%+4.17%+3.01%+1.16%-2.68%
30d6+50.00%-5.47%+2.21%-7.68%-9.91%
60d6+50.00%-8.50%+1.19%-9.69%-10.88%
90d6+33.33%-13.81%+0.21%-14.03%-32.21%
180d6+33.33%-25.12%-1.14%-23.98%-44.16%
1y6+33.33%+34.31%+5.87%+28.43%+10.44%
2y6(2 pending)+25.00%-11.03%+15.85%-26.89%-46.37%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
PDSB · 161,200 shares · as of Jan 5, 2023
050,700101,400152,100202,80020222023SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 13 buys / 0 sellsCOVERAGE · 19 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
APYX
APYX MEDICAL CORP
PURCHASEGRANT
Stock grant
132,066132,066Jun 11, 2026Jun 15, 2026View →
APYX
APYX MEDICAL CORP
PURCHASEGRANT
Stock grant
100,000100,000May 15, 2025May 19, 2025View →
APYX
APYX MEDICAL CORP
PURCHASEGRANT
Stock grant
50,00050,000Jan 15, 2025Jan 17, 2025View →
APYX
APYX MEDICAL CORP
PURCHASE
Chief Financial Officer
6,000$1.13$6.8K8,500Aug 13, 2024Mar 3, 2025View →
APYX
APYX MEDICAL CORP
PURCHASE
Chief Financial Officer
5,336$1.13$6.0K7,836Aug 13, 2024Aug 13, 2024View →
APYX
APYX MEDICAL CORP
PURCHASEGRANT
Stock grant
150,0000Jan 10, 2024Jan 11, 2024View →
APYX
APYX MEDICAL CORP
PURCHASE
Chief Financial Officer
2,500$2.19$5.5K2,500Dec 12, 2023Dec 14, 2023View →
PDSB
PDS BIOTECHNOLOGY CORP
PURCHASEGRANT
Stock grant
161,200161,200Jan 5, 2023Jan 6, 2023View →
PDSB
PDS BIOTECHNOLOGY CORP
PURCHASE
Chief Financial Officer
100$9.00$9004,075Dec 13, 2021Dec 14, 2021View →
PDSB
PDS BIOTECHNOLOGY CORP
PURCHASE
Chief Financial Officer
2,500$9.00$22.5K3,475Dec 13, 2021Dec 14, 2021View →
PDSB
PDS BIOTECHNOLOGY CORP
PURCHASE
Chief Financial Officer
100$9.00$9003,975Dec 13, 2021Dec 14, 2021View →
PDSB
PDS BIOTECHNOLOGY CORP
PURCHASE
Chief Financial Officer
400$8.90$3.6K3,875Dec 13, 2021Dec 14, 2021View →
PDSB
PDS BIOTECHNOLOGY CORP
PURCHASEGRANT
Stock grant
202,800202,800Oct 19, 2021Oct 20, 2021View →
Other insiders · PDSB
Loading peer insiders…
About this filer
CIK 0001278675
ROLE
Chief Financial Officer
PRIMARY
PDSB
COMPANIES
2
ACTIVE SINCE
Oct 2021
MARKETPEEL · /INSIDER/0001278675DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback